Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Announces Launch of Full-Service Telehealth SolutionApril 11, 2022

Platform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari

Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for HaematologyApril 07, 2022

Sickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline. Adverse Events Among These Patients from French Guiana and Qatar were Few and Mild

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business UpdateMarch 31, 2022

Emmaus Life Sciences, Inc. today reported financial results for the year ended December 31, 2021 and an update on recent activities.

Emmaus Life Sciences Announces Endari To Be Added to the Florida Medicaid Preferred Drug ListMarch 29, 2022

Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for EndariMarch 23, 2022

Emmaus Life Sciences, Inc. today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.